Top Genetics Research Papers

Overall: Randomized evidence supports a modest reduction in breast cancer with estrogen-only therapy after hysterectomy, but incomplete harm assessment and observational BRCA evidence limit definitive practice change.

Overall: This uncontrolled but informative five-year extension reports substantial survival, respiratory, feeding, and motor benefits with no new safety signal, while its small selected cohort and lack of a comparator limit causal certainty and independent practice-changing impact.

Overall: Small uncontrolled studies provide encouraging long-term evidence of major reductions in severe infections and bleeding, but treatment is complex and the estimates remain vulnerable to bias.

Overall: Clinical Characteristics and Outcomes of Hypertrophic Cardiomyopathy Associated With Thin Filament Variants: Insights From the SHaRe Registry identifies important genotype-associated risks in a large cohort, but retrospective design and the absence of evidence that genotype-guided care improves outcomes limit immediate practice change.

Overall: This relevant US randomized trial found no short-term improvement from genotype-guided SSRI prescribing but identified a potentially meaningful secondary remission benefit at six months that requires further confirmation.

Overall: This large, long-term cohort provides credible evidence that the number of affected relatives may improve colorectal cancer risk stratification in inflammatory bowel disease, but it does not show that changing surveillance improves patient outcomes.

Overall: This large cohort provides clinically useful cancer-risk estimates across BRCA result categories, but it does not demonstrate that a specific change in screening or prevention improves patient outcomes.

Overall: This large-scale evaluation shows promising diagnostic yield and workflow efficiency for automated genomic reanalysis, but lacks comparative validation and evidence that additional diagnoses improve patient outcomes.

Overall: This large national cohort links regular surveillance with lower mortality, but unquantified effects, possible selection bias, lack of stage shift, and possible overdiagnosis limit causal interpretation and immediate practice-changing value.

Overall: This large genomic association study provides credible evidence that heterozygous MSH3 and possibly MLH3 variants increase colorectal cancer risk, but it lacks absolute-risk estimates and evidence that testing improves clinical outcomes.